Systemic Bcl‐2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice

No abstract is available for this paper.

• Publication year

  2006

• Venue

  International Journal of Cancer

• Publication date

  2006-07-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.21804PMID 16477627
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts.

  2005cited by this paper
• Antisense therapy for cancer

  2005cited by this paper
• Antitumor Efficacy of Oblimersen Bcl-2 Antisense Oligonucleotide Alone and in Combination with Vinorelbine in Xenograft Models of Human Non–Small Cell Lung Cancer

  2004cited by this paper
• Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities

  2004cited by this paper
• CpG oligonucleotides elicit antitumor responses in a human melanoma NOD/SCID xenotransplantation model.

  2004cited by this paper
• Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.

  2004cited by this paper
• Pathogenesis and treatment of nasopharyngeal carcinoma.

  2004cited by this paper
• Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides

  2004cited by this paper
• Antisense RNA Down-Regulation of bcl-2 Expression in DU145 Prostate Cancer Cells Does Not Diminish the Cytostatic Effects of G3139 (Oblimersen)

  2004cited by this paper
• Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity

  2003cited by this paper
• Significance of c-Myc and Bcl-2 protein expression in nasopharyngeal carcinoma.

  2003cited by this paper
• Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.

  2003cited by this paper
• Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice.

  2003cited by this paper
• Epstein-Barr Virus Latent Membrane Protein 1: Structure and Functions

  2003cited by this paper
• Oblimersen Bcl-2 Antisense: Facilitating Apoptosis in Anticancer Treatment

  2002cited by this paper
• Epstein-Barr virus in the pathogenesis of NPC.

  2002cited by this paper
• The significance of LMP1 expression in nasopharyngeal carcinoma.

  2002cited by this paper
• Expression of Epstein-Barr virus latent membrane protein 1 and B-cell leukemia-lymphoma 2 gene in nasopharyngeal carcinoma tissues.

  2002cited by this paper
• Antitumor Effect of G3139 Bcl-2 Antisense Oligonucleotide Is Independent of Its Immune Stimulation by CpG Motifs in SCID Mice

  2002cited by this paper
• Bcl-2 and LMP1 expression in nasopharyngeal carcinomas.

  2001cited by this paper
• Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen.

  2001cited by this paper
• Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model

  2001cited by this paper
• Association of p53 and BCL‐2 expression with Epstein‐Barr virus infection in the cancers of head and neck

  2001cited by this paper
• Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.

  2000cited by this paper
• Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.

  2000cited by this paper
• Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.

  2000cited by this paper
• Co-expression of p53 and bcl-2 may correlate to the presence of epstein-barr virus genome and the expression of proliferating cell nuclear antigen in nasopharyngeal carcinoma.

  2000cited by this paper
• Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide.

  2000cited by this paper
• Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA.

  2000cited by this paper
• Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma.

  1999cited by this paper
• Nasopharyngeal carcinoma cell line (C666‐1) consistently harbouring Epstein‐Barr virus

  1999cited by this paper
• bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

  1998cited by this paper
• Analysis of bcl-2 expression in normal, inflamed, dysplastic nasopharyngeal epithelia, and nasopharyngeal carcinoma: association with p53 expression.

  1997cited by this paper
• Antisense therapy for cancer.

  1995cited by this paper
• Bcl‐2 proto‐oncogene expression in epstein‐barr‐virus‐associated nasopharyngeal carcinoma

  1993cited by this paper
• Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death.

  1991cited by this paper

• Assessment of anti-cancer activity of cyclovirobuxine D in nasopharyngeal carcinoma cells: Involvement of KIF23-mediated Akt/mTOR pathway.

  2025cites this paper
• ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.

  2018cites this paper
• Apogossypolone, a small-molecule inhibitor of Bcl-2, induces radiosensitization of nasopharyngeal carcinoma cells by stimulating autophagy.

  2014cites this paper
• Therapeutic Induction of Apoptosis in Nasopharyngeal Carcinoma

  2013cites this paper
• Recent Advances in Nasopharyngeal Carcinoma Research and its Pathogenesis

  2012cites this paper
• Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects

  2011cites this paper
• Bcl-2 targeted-therapy for the treatment of head and neck squamous cell carcinoma.

  2011cites this paper
• Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents.

  2010cites this paper
• Update on EBV monitoring, detection and therapy in PTLD after solid organ transplant

  2010cites this paper
• ELECTROSPRAY IONIZATION MASS SPECTROMETRY FOR THE CHARACTERIZATION OF COVALENT AND NONCOVALENT POLYNUCLEAR PLATINUM COMPOUNDS INTERACTING WITH BIO-MOLECULES

  2010cites this paper
• Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response.

  2010cites this paper
• Targeting the Bcl-2

  2009cites this paper
• Hepatocyte growth factor suppresses tumor cell apoptosis in nasopharyngeal carcinoma by upregulating Bcl-2 protein expression.

  2009cites this paper
• Gold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo

  2009cites this paper
• Herpesviridae and novel inhibitors

  2009cites this paper
• Optimizing approaches to head-and-neck cancers. Viruses in head-and-neck cancers: prevention and therapy.

  2008cites this paper
• Viruses in head and neck cancers: prevention and therapy

  2008cites this paper
• Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

  2008cites this paper
• ApoG2, a novel inhibitor of antiapoptotic Bcl‐2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts

  2008cites this paper
• Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion

  2008cites this paper
• Serum epstein-barr virus as a biomarker in nasopharyngeal carcinoma

  2008influential citation
• Why G3139 works poorly in cancer trials but might work well against HIV

  2007cites this paper
• Nasopharyngeal carcinoma: molecular biomarker discovery and progress

  2007cites this paper